Compare TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock vs 10X Genomics Inc — how do they compare? TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.44 (market cap $39.15B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 3.9× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days and 10X Genomics Inc for 91 Days on average.
| TTWO | TXG | |
|---|---|---|
Market Cap | $39.15B | $10.07B |
Volume | 2,708,429 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $262.29 | $97.74 |
52-Week Low | $189.69 | $11.48 |
Typical Hold Time | 111 Days | 91 Days |
Enterprise Value | $40.27B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Take-Two Interactive (TTWO) trades at $209.37, up 2.63% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, while the company reaffirmed the GTA VI launch date for November 19, 2026. Financials reveal negative net income margins and elevated debt levels, though revenue growth is projected to $6.7B in 2026. The stock is near its pivot point of $209, with support at $206 and resistance at $212.
The outlook hinges on GTA VI's successful launch driving revenue growth and profitability improvements. Risks include execution challenges, competitive pressures, and high valuation multiples. Analyst optimism, with a $292.30 price target, suggests significant upside if operational targets are met, but investors must weigh near-term losses against long-term game release catalysts.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
